DJIA 17,598.20 -91.66 -0.52%
NASDAQ 5,115.38 -12.90 -0.25%
S&P 500 2,098.04 -5.80 -0.28%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

70.33 0.31 (0.44%)

Quote as of


company name or ticker

Recent Quotes

ALKS $70.33 0.44%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $69.61
Previous Close $70.02
Daily Range $69.20 - $71.11
52-Week Range $38.49 - $75.17
Market Cap $10.5B
P/E Ratio -118.68
Dividend (Yield) $0.00 (0.0%)
Volume 743,610
Average Daily Volume 952,506
Current FY EPS -$1.02

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary Rss Feed

Why I Think Alkermes Could Be a Top Performing Stock Ahead of 2016

Upcoming catalysts including new drugs for schizophrenia and depression could send Alkermes shares soaring.

Alkermes' Reports Wider Q2 Loss, Increases Guidance - Analyst Blog

Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On

Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On Debut

Alkermes' (ALKS) CEO Richard Pops on Q2 2015 Results - Earnings Call Transcript

Alkermes (ALKS) Q2 2015 Results - Earnings Call Webcast

Will McKesson (MCK) Keep the Earnings Streak Alive? - Analyst Blog

Will Express Scripts (ESRX) Miss Earnings Estimates in Q2? - Analyst Blog

Xenoport Not Getting Much Love Ahead Of Key Data

Midyear Report Card: Grading My Biotech Predictions for 2015

One Foolish investor shines a bright light on his biotech stocks predictions for this year.

5 Big Upcoming FDA Decisions Expected in July

See More ALKS News...

ALKS's Top Competitors

ALKS $70.33 (0.44%)
Current stock: ALKS
AMGN $175.59 (-0.57%)
Current stock: AMGN
GILD $119.60 (1.48%)
Current stock: GILD
BIIB $324.38 (1.76%)
Current stock: BIIB